Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.340
-0.120-0.38%
Volume:2.09M
Turnover:65.99M
Market Cap:189.76B
PE:42.51
High:31.880
Open:31.460
Low:31.340
Close:31.460
52wk High:44.220
52wk Low:19.601
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:0.51
T/O Rate:0.03%
Dividend:0.37
Dividend Rate:1.17%
EPS(LYR):0.737
ROE:16.21%
ROA:8.35%
PB:5.39
PE(LYR):42.51
PS:12.71

Loading ...

Hansoh Pharmaceutical Group Stock Advances 1.6% in Hong Kong

Dow Jones
·
Mar 05

Hansoh Pharmaceutical Group Stock Slips 3.1% in Hong Kong

Dow Jones
·
Mar 03

Hansoh Pharma (03692) Publishes Monthly Return for February 2026

Bulletin Express
·
Mar 02

UBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick

Stock News
·
Mar 02

Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets

Simply Wall St.
·
Mar 01

Hansoh Pharma reports ESGO 2026 PSOC data for B7-H4 ADC mocertatug rezetecan HS-20089

Reuters
·
Feb 28

Hansoh Pharma reports Phase 2 ASCO GU 2026 data for risvutatug rezetecan in mCRPC

Reuters
·
Feb 28

Hansoh Pharmaceutical (3692) Announces NMPA Acceptance of New Drug Application

Bulletin Express
·
Feb 27

Hansoh Pharmaceutical - New Drug Application of Dalmelitinib Mesylate Tablets Accepted by Nmpa

THOMSON REUTERS
·
Feb 27

China NMPA Accepts Hansoh Dalmelitinib NDA for EGFR-Mutant NSCLC

Reuters
·
Feb 27

Hansoh Pharmaceutical Group Stock Rallies 2.2% in Hong Kong

Dow Jones
·
Feb 27

Hansoh Pharmaceutical Group Stock Falls 6.4% in Hong Kong

Dow Jones
·
Feb 24

Hansoh Pharma's Aumolertinib Approved in EU for Lung Cancer Treatment

MT Newswires Live
·
Feb 20

Hong Kong Stock Announcement Highlights: Insilico, Seyond, and CF Pharmtech Added to Hang Seng Composite Index Constituents

Stock News
·
Feb 20

Hansoh Pharma (3692) Obtains EU Approval for Aumolertinib Mesylate Tablets as Monotherapy

Bulletin Express
·
Feb 20

HANSOH PHARMA's Aumseqa® Receives EU Marketing Authorization as Monotherapy

Stock News
·
Feb 20

Hansoh Pharmaceutical - Aumolertinib Mesylate Tablets Approved in EU as Monotherapy

THOMSON REUTERS
·
Feb 20

EU approves Hansoh’s aumolertinib mesylate tablets as monotherapy for advanced EGFR-mutated NSCLC

Reuters
·
Feb 20

Hansoh Pharmaceutical Group Stock Climbs 1.7% in Hong Kong

Dow Jones
·
Feb 16

Hansoh Pharmaceutical Group Stock Slips 2.5% in Hong Kong

Dow Jones
·
Feb 13